AngioDynamics, Inc. (NASDAQ:ANGO) Receives $18.67 Average Price Target from Analysts

Posted by Brenda Bartman on Jun 19th, 2026

AngioDynamics, Inc. (NASDAQ:ANGO – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $18.6667.

A number of equities research analysts recently issued reports on ANGO shares. Freedom Capital upgraded shares of AngioDynamics to a “strong-buy” rating in a research report on Monday, April 6th. Zacks Research cut shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. Canaccord Genuity Group dropped their price target on AngioDynamics from $18.00 to $16.00 and set a “buy” rating for the company in a report on Monday, April 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a report on Monday, April 20th.

View Our Latest Research Report on AngioDynamics

AngioDynamics Trading Up 3.5%

Shares of ANGO opened at $12.15 on Friday. AngioDynamics has a 1 year low of $8.36 and a 1 year high of $13.99. The stock has a 50 day simple moving average of $11.25 and a 200-day simple moving average of $11.37. The stock has a market cap of $502.04 million, a PE ratio of -16.20 and a beta of 0.38.

AngioDynamics (NASDAQ:ANGO – Get Free Report) last issued its earnings results on Thursday, April 2nd. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. The business had revenue of $78.42 million during the quarter, compared to analysts’ expectations of $76.77 million. AngioDynamics had a negative return on equity of 4.66% and a negative net margin of 10.01%. On average, sell-side analysts forecast that AngioDynamics will post -0.19 EPS for the current fiscal year.

Institutional Investors Weigh In On AngioDynamics

A number of hedge funds and other institutional investors have recently bought and sold shares of ANGO. Goldman Sachs Group Inc. increased its holdings in AngioDynamics by 9.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock valued at $2,434,000 after purchasing an additional 22,658 shares in the last quarter. Jane Street Group LLC increased its position in AngioDynamics by 267.1% in the 1st quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier’s stock valued at $439,000 after acquiring an additional 34,054 shares in the last quarter. Legal & General Group Plc increased its position in AngioDynamics by 279.5% in the 2nd quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier’s stock valued at $123,000 after acquiring an additional 9,098 shares in the last quarter. Rhumbline Advisers increased its position in AngioDynamics by 4.3% in the 2nd quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock valued at $608,000 after acquiring an additional 2,510 shares in the last quarter. Finally, American Century Companies Inc. increased its position in AngioDynamics by 15.8% in the 2nd quarter. American Century Companies Inc. now owns 96,808 shares of the medical instruments supplier’s stock valued at $960,000 after acquiring an additional 13,217 shares in the last quarter. 89.43% of the stock is owned by institutional investors and hedge funds.

About AngioDynamics

(Get Free Report)

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.